Shots:

• The CHMP recommendation is based on P-III CheckMate -9ER trial involves assessing Opdivo + Cabometyx vs sunitinib in 651 patients with previously untreated advanced or metastatic RCC
• The P-III result showed improvements in PFS- OS and ORR with consistent efficacy benefits observed across key subgroups of patients and was well tolerated- with a low rate of treatment-related discontinuations
• The EC has the authority to approve medicines for the EU and now review the CHMP recommendation. The findings were presented at Presidential Symposium at the ESMO Virtual Congress 2020

 ­ Ref: BMS | Image: BMS